| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(4 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(3 years from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(3 years from now) | |
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(4 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(4 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(4 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(5 years from now) | |
Jakafi is owned by Incyte Corp.
Jakafi contains Ruxolitinib Phosphate.
Jakafi has a total of 16 drug patents out of which 0 drug patents have expired.
Jakafi was authorised for market use on 16 November, 2011.
Jakafi is available in tablet;oral dosage forms.
Jakafi can be used as for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2.; for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy, for the treatment of polycythemia vera; for the treatment of intermediate or high-risk myelofibrosis; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea, for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of steroid-refractory acute graft-versus-host disease (agvhd), for treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd), for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf.
The generics of Jakafi are possible to be released after 22 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 22, 2028 |
| New Indication (I) | Sep 22, 2024 |
| M (M) | Dec 19, 2025 |
| Pediatric Exclusivity (PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treatment of polycythemia vera (pv) in patients who have had an inadequate respons...
Dosage: TABLET;ORAL
JAKAFI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic